Amyris to acquire Oobli, adding fermentation-derived sweet proteins

Amyris plans to acquire Oobli, pairing its manufacturing scale and strain engineering with Oobli's fermentation-derived sweet protein platform aimed at sugar reduction.

Amyris, Inc. has announced that it will acquire Oobli Inc., a Davis, California-based specialist in fermentation-derived sweet proteins. The Emeryville, California-based biomanufacturing company said the transaction is expected to close in the coming weeks.

Amyris describes itself as a vertically integrated biomanufacturing company. Oobli produces fermentation-based sweet protein ingredients for food and beverage brands seeking to reduce sugar without sacrificing taste.

Combining platforms

The acquisition is intended to bring together Amyris's scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. It follows Amyris's expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris frames the deal as a strategic commercial and technology expansion that is expected to accelerate its work in protein- and peptide-based solutions across end markets.

Kathy Fortmann, Amyris's chief executive officer, said Oobli offers a commercial and technology platform that complements Amyris's own. According to Fortmann, Oobli is positioned to change how sweetness reaches the market, and Amyris's commercial scale and resources could help accelerate that effort. She added that combining Oobli's protein expertise with Amyris's strain engineering, manufacturing scale and commercial capabilities could broaden the combined company's work in food and beverage, personal care, flavor and fragrance, agriculture and other areas.

Sweet protein portfolio

Oobli's sweet protein portfolio is expected to be the first to benefit from the combined platform. The company says it has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries near the equator. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category. They are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, according to the company, providing sweetness without gut disruption or blood sugar spikes.

The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli says the ingredients have FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor. The company is targeting applications across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, where brands are responding to consumer interest in metabolic health and sugar reduction.

Scale and continuity

Ali Wing, Oobli's chief executive officer, said the company has long believed there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. Wing said Oobli is proud of the breakthroughs it has achieved and that joining Amyris would provide the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.

Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform supports sweet taste, sugar reduction and clean label goals at the same time. She said Amyris is eager to welcome the Oobli team and realize synergies between the two platforms.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli's sweet protein portfolio expands within the larger company.

KS

Kavya Sridhar

Kavya Sridhar covers fine chemicals, electronic chemicals, and strategic sourcing across synthesis intermediates, high-purity wet chemicals, and battery electrolytes. Her reporting relies on measurable evidence such as impurity profiles, residual solvent levels, trace metals, particle counts, moisture content, and batch-to-batch variation documented in certificates of analysis. She writes for QC chemists, process engineers, regulatory specialists, and sourcing leads who must qualify a second supplier, compare total landed cost, and confirm specification limits without treating a supplier statement as a compliance conclusion.